News
FDA approves Lucentis to treat diabetic retinopathy
On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy…
FDA approves first generic version of Nexium
On January 26, the U.S. Food and Drug Administration (FDA) approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules) to treat gastroesophageal…
FDA permits marking of mobile app for glucose monitoring
On January 23, the U.S. Food and Drug Administration (FDA) permitted marketing of the first set of mobile medical apps that allow people with…
FDA approves Ibrance for postmenopausal women with metastatic breast cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
FDA approves tissue adhesive for internal use
On February 4, the U.S. Food and Drug Administration (FDA) approved TissuGlu, the first tissue adhesive approved for internal use. TissuGlu is a urethane-based…
FDA to strengthen review of AEDs
On January 28, the U.S. Food and Drug Administration (FDA) announced that it will strengthen its review of automated external defibrillators (AEDs) to help…
FDA approves new drug for psoriasis
On January 21, the U.S. Food and Drug Administration (FDA) approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Read more.
FDA approves new anticlotting drug
On January 8, the U.S. Food and Drug Administration (FDA) approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and…
FDA approves device to treat obesity
On January 14, the U.S. Food and Drug Administration (FDA) approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment…
FDA authorizes use of Ebola test
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to authorize use of the LightMix® Ebola Zaire rRT-PCR Test…
FDA approves Lucentis to treat diabetic retinopathy
On February 6, the U.S. Food and Drug Administration (FDA) expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat…
FDA approves first generic version of Nexium
On January 26, the U.S. Food and Drug Administration (FDA) approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules) to…
FDA permits marking of mobile app for glucose monitoring
On January 23, the U.S. Food and Drug Administration (FDA) permitted marketing of the first set of mobile medical apps that allow…
FDA approves Ibrance for postmenopausal women with metastatic breast cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved Ibrance (palbociclib) to treat advanced metastatic breast cancer. Read more.
FDA approves tissue adhesive for internal use
On February 4, the U.S. Food and Drug Administration (FDA) approved TissuGlu, the first tissue adhesive approved for internal use. TissuGlu is…
FDA to strengthen review of AEDs
On January 28, the U.S. Food and Drug Administration (FDA) announced that it will strengthen its review of automated external defibrillators (AEDs)…
FDA approves new drug for psoriasis
On January 21, the U.S. Food and Drug Administration (FDA) approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Read more.
FDA approves new anticlotting drug
On January 8, the U.S. Food and Drug Administration (FDA) approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of…
FDA approves device to treat obesity
On January 14, the U.S. Food and Drug Administration (FDA) approved the Maestro Rechargeable System for certain obese adults, the first weight…
FDA authorizes use of Ebola test
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to authorize use of the LightMix® Ebola Zaire…
Poll
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.